Tirzepatide
Dual GLP-1 and GIP receptor agonist.
View treatment
Semaglutide
Compounded semaglutide · dose personalized to you
From $149/mo
The most-studied GLP-1 for weight management. Semaglutide mimics the gut hormone that signals fullness and slows digestion, so appetite is easier to work with rather than fight. A licensed provider reviews your intake, sets your titration, and adjusts it as your body changes.
- No insurance required
- Licensed U.S. providers
- Pharmacies we name
- Founded by patients
- Fast, discreet shipping
- Unlimited follow-up with your clinician
$0 Membership fees
See If You Qualify Not sure? See all plans and pricing You choose your plan during the medical intake. Your per-month price never climbs with your dose.
Before you decide
What is compounded semaglutide — and is it safe?
The honest version, sourced, before any pricing.
Compounded semaglutide is the same active molecule class as Ozempic® and Wegovy® — a GLP-1 receptor agonist — prepared as an individual prescription by a state-licensed US compounding pharmacy instead of by Novo Nordisk. It is not FDA-approved and is not a generic version of Ozempic® or Wegovy®; compounded preparations are legal under the FDA's 503A/503B framework but are not clinically studied as finished products.
The underlying molecule, semaglutide 2.4 mg, is one of the most-studied weight-loss medications in history: in the STEP 1 trial (n = 1,961), adults lost an average of 14.9% of body weight over 68 weeks vs 2.4% on placebo (NEJM 2021, DOI 10.1056/NEJMoa2032183). The most common side effects are temporary nausea and stomach upset during dose titration.
What makes a compounded program safe is the oversight around it: a licensed US provider reviewing your history and contraindications, a LegitScript-certified platform, a state-licensed pharmacy, and dose titration managed by a clinician — all of which REMEVi provides in English and Spanish. If you don't qualify medically, you get a full refund.
Content last updated: · Sources: New England Journal of Medicine (STEP 1), FDA compounding guidance. Read the full evidence review on our Science page.
How it works
Works with your appetite, not against it.
Semaglutide is a GLP-1 receptor agonist. Receptors sit in the brain, gut and pancreas, where activation supports appetite regulation and metabolic function.
Activates GLP-1 receptors
Semaglutide mimics the GLP-1 your gut already releases after a meal, acting on the same receptors that signal fullness to the brain.
Signals satiety for days, not minutes
The GLP-1 your gut makes is broken down by the DPP-4 enzyme within minutes. A receptor agonist is engineered to keep signalling long enough for once-weekly dosing.
Slows gastric emptying
Food leaves the stomach more gradually, which extends the feeling of fullness after a meal and is also why dose titration matters for tolerability.
The evidence
What the trials actually measured.
One of the most-studied weight-management medications ever trialled.
STEP 1 randomised 1,961 adults with overweight or obesity to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Results are for the active medication studied in the trial, not for REMEVi patients — individual results vary.
−14.9% Mean body-weight reduction vs −2.4% on placebo
68 weeks Trial duration · n = 1,961
Source: Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1), New England Journal of Medicine, 2021. DOI 10.1056/NEJMoa2032183.
Natural GLP-1 lasts minutes. A receptor agonist lasts days.
Every time you eat, your gut releases GLP-1, which signals fullness and slows digestion — and an enzyme called DPP-4 destroys it almost immediately. Receptor agonists are built to resist that breakdown, which is what makes a single weekly injection possible instead of dosing after every meal.
1–2 min How long the GLP-1 your gut produces stays active
up to ~5,000× Longer-lasting than the natural hormone across the class (2.5 hours to ~7 days)
Source: Nauck MA, Meier JJ, "Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes?", European Journal of Endocrinology, 2019; Gentilella R et al., Diabetes/Metabolism Research and Reviews, 2019.
The dose is stepped up deliberately, not started high.
Your provider begins low and increases every four weeks, because most gastrointestinal side effects track with how fast the dose rises rather than the final dose itself. Personalised titration is the specific clinical reason a compounded preparation may be appropriate.
4 weeks Between dose steps
Unlimited Provider messages while titrating
Source: REMEVi clinical protocol; your provider adjusts the schedule to your response and tolerability.
Stopping is what undoes it.
STEP-4 is the trial most programs never mention, and the one that should shape how you budget. Patients who continued treatment held their loss; patients switched to placebo regained. That is why REMEVi prices for the long run rather than discounting a first month you are then meant to grow out of.
+6.9% Regained after withdrawal
n = 803 Randomized · continued vs withdrawn
Source: Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight Maintenance. JAMA 2021;325:1414–1425. doi:10.1001/jama.2021.3224
Trial figures describe the active medication studied, not compounded preparations or REMEVi outcomes, and are not a guarantee of individual results. Compounded medications are not FDA-approved drug products.
How REMEVi works
Reviewed within 24 hours, shipped in one to three days.
See If You Qualify
A licensed provider decides whether treatment is appropriate — nobody is prescribed automatically.
-
Step 1Medical intake
A guided set of questions covering your history, current medications, and goals.
About 5 minutes -
Step 2Clinician review
A licensed provider in your state reviews your intake and prescribes only if it is clinically appropriate.
Within 24 hours -
Step 3Pharmacy and shipping
A named, state-licensed pharmacy fills your prescription and ships it cold-chain in discreet packaging.
Ships 1–3 days after approval -
Step 4Follow-up, in your language
Message your care team as often as you need for dose adjustments and side-effect support, in English or Spanish.
Unlimited, every month
Some states require a live audio or video consultation before a prescription can be approved, which can add a day or two.
Explore other treatments
Semaglutide
The most-studied GLP-1 for weight management.
Oral semaglutide
Daily tablet for needle-free dosing.
View treatment
NAD+ injections
Replenish NAD+, which declines with age.
View treatment
Sermorelin
Stimulates the pituitary's own growth hormone.
View treatment
Glutathione
Antioxidant support against oxidative stress.
View treatmentTreatment plan
Semaglutide dosing protocol
Provider-supervised dose escalation over 20 weeks to maximize results and minimize side effects.
Dose escalation
Weeks 1–4
0.25 mg
Starter dose weekly
Weeks 5–8
0.5 mg
Increased weekly
Weeks 9–16
1.0 mg
Therapeutic dose
Weeks 17+
2.0 mg
Maintenance dose
Delivery & support
Injection method
Subcutaneous (under the skin)
Frequency
Once per week
Provider check-ins
Monthly dose adjustments
Timeline
20 weeks to full dose
What to expect
Semaglutide results timeline
Weight loss milestones and what patients typically experience at each phase.
Week 2–4
Appetite reduction
Noticeable decrease in hunger and food cravings.
Month 2–3
Noticeable loss
Weight loss becomes visible; clothes fit differently.
Month 4–6
10–15% loss
Average body weight reduction of 10–15%.
Month 6+
15%+ loss
Continued loss with maintenance dose.
Results vary based on adherence, diet, exercise, and individual metabolism. Your REMEVi licensed provider will monitor your progress and adjust dosing as needed.
Why REMEVi Health
The clinical standard, personalized to your goals.
Licensed U.S. providers
A clinician licensed in your state reviews every intake and sets your titration. No wait lists, no insurance required.
One flat price
Your per-month price never climbs with your dose. No membership fee, no lab fee, no dose upcharge.
Named pharmacies
We publish which state-licensed compounding pharmacies fill our prescriptions, and the name appears on your vial label.
Bilingual care
Real people on WhatsApp in English and Spanish — the reason REMEVi exists, not an add-on service tier.
The REMEVi Flat-Dose Guarantee
Your price never rises with your dose. Ever.
Most programs charge more as your dose increases. At REMEVi, your price stays flat at every dose — with no separate membership fee on top of the medication price.
THE 4 QUESTIONS EVERYONE ASKS
Named out loud, answered in full.
REMEVi's semaglutide is compounded by a 503B outsourcing facility registered with the FDA — the same regulatory tier hospitals use. Compounded medications are not FDA-approved finished drug products; they are prepared under the 503A or 503B framework to USP <797> sterility standards and prescribed by a licensed provider in your state who will review the risks, benefits, and considerations with you.
Facility tier
FDA-registered 503B
Sterility standard
USP <797>
Active ingredient
Semaglutide
Provider network
All 50 states + DC
FAQ
Semaglutide questions answered
Semaglutide is a GLP-1 receptor agonist — a medication that mimics the glucagon-like peptide-1 hormone. It works by reducing appetite, slowing stomach emptying, and improving blood sugar control. Originally developed for type 2 diabetes, the GLP-1 class has been extensively studied for weight management.
Compounded medications are not FDA-approved finished drug products. They are prepared under the 503A or 503B regulatory framework by state-licensed compounding pharmacies and are subject to USP standards. Every REMEVi patient is evaluated by a licensed provider before any medication is dispensed, and your provider will review the risks, benefits, and contraindications of compounded semaglutide with you before prescribing.
The most common side effects are nausea, vomiting, diarrhea, and constipation — especially when starting or increasing the dose. These typically resolve within a few weeks. Serious side effects are rare; your licensed provider will discuss all risks during your evaluation.
Most patients notice reduced appetite within the first 2–4 weeks. Meaningful weight loss typically begins at weeks 4–8 as the dose increases. Average results at 6 months range from 10–20% body weight reduction depending on lifestyle factors.
GLP-1 medications can be used long-term under your provider's supervision. Many patients maintain a lower dose after reaching their goal weight. Your REMEVi licensed provider will create a sustainable long-term plan with you.
Disclaimer: This page is for educational purposes and is not medical advice, diagnosis or treatment. Compounded semaglutide is not FDA-approved and is not a generic version of Ozempic® or Wegovy®. Your provider prescribes a compounded preparation only when they determine it offers a meaningful clinical difference for you — such as personalized dose titration. Eligibility and prescriptions are determined solely by licensed medical providers based on clinical appropriateness; not everyone will qualify. Trial results describe the active medication studied, not REMEVi outcomes. Individual results vary.
The GLP-1 Guide · Free
Not ready to start today? Take the guide with you.
What GLP-1 is, how it works, what to expect, and nutrition tips — in English and Spanish. Free, straight to your inbox.
No spam. Unsubscribe anytime.